Battered and bruised Seres Therapeutics see shares skyrocket on phase 3 win

Battered and bruised Seres Therapeutics see shares skyrocket on phase 3 win

Source: 
Fierce Biotech
snippet: 

Seres Therapeutics has endured a tough few years of trials setbacks, cuts and new management, but the GI biotech is hoping with its new set of broadly positive late-stage data it can finally file for an approval.

The Cambridge, Massachusetts-based biotech said Monday morning that its pivotal phase 3 test, known as ECOSPOR III, which was testing its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI) came through.